ClinicalTrialsFinder
RecruitingNCT06383858

The Project of Gestational Hypertension and Preeclampsia Screening and Prevention Center

The Project of Gestational Hypertension and Preeclampsia Screening and Prevention

Sponsor

The Third Affiliated Hospital of Guangzhou Medical University

Enrollment

50,000 participants

Start Date

Aug 1, 2023

Study Type

OBSERVATIONAL

Conditions

PreeclampsiaMaternal Deaths

Summary

Preeclampsia is the main cause of illness and death in pregnant women and fetuses. Currently, there is no effective treatment for preeclampsia in clinical practice, and the fundamental treatment is still termination of pregnancy and placental delivery. Therefore, early prediction of preeclampsia and targeted strengthening of high-risk pregnant women supervision, early intervention and diagnosis and treatment can greatly reduce the serious obstetric complications and perinatal maternal and fetal deaths caused by preeclampsia, which has significant social and clinical significance.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is setting up a screening and prevention program for high blood pressure disorders during pregnancy, specifically gestational hypertension and preeclampsia — a serious condition that can develop in late pregnancy and affect both mother and baby. **You may be eligible if...** - You are pregnant and have been assessed for preeclampsia risk based on your clinical history - You are having routine blood pressure and protein marker testing during your first, second, or third trimester - You are willing to join and sign an informed consent form **You may NOT be eligible if...** - Your baby has a severe abnormality or there is no heartbeat detected - You were already taking aspirin regularly before joining - Your doctor feels there are other reasons you should not participate - You will be difficult to follow up for delivery information Talk to your doctor to see if this trial is right for you.

This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Print for Your DoctorCheck Your Eligibility

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTScreening method

All pregnant women in the group were screened for pre-eclampsia risk according to the clinical risk factors listed in NICE Guidelines (2019).

DIAGNOSTIC_TESTScreening method

In the first trimester, pregnant women with routine MAP and PLGF (with UtA-PI detection conditions plus UtA-PI) were tested, and the risk of preeclampsia was evaluated based on Bayes rule combined with maternal factors. In the second and third trimester of pregnancy, routine determination of PLGF or sFlt-1/PLGF was used to evaluate the risk of preeclampsia.

Locations(1)

FANG HE

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06383858

Related Trials

Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories

NCT070412813 locations

Dietary Salicylates and Preeclampsia

NCT062393631 location

Placental Imaging Techniques

NCT068613091 location

Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy

NCT0348718514 locations

Vascular Effects of High-Salt After Preeclampsia

NCT067494181 location